Management of urgent high-risk cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and coexisting disorders of renal function: use of heparin and epoprostenol combined with on-line monitoring of platelet function.
Mertzlufft
F
F
Department of Anesthesiology and Critical Care Medicine, Universitaetskliniken des Saarlandes, Homburg-Saar, Germany.
Kuppe
H
H
Koster
A
A
D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage*; D001792:Blood Platelets / Q000502:physiology*; D001803:Blood Transfusion; D002315:Cardiopulmonary Bypass; D011464:Epoprostenol / Q000008:administration & dosage*; D006493:Heparin / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007674:Kidney Diseases / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D011182:Postoperative Care; D013921:Thrombocytopenia / Q000139:chemically induced*
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D011464:Epoprostenol